Perioperative Use of Tranexamic Acid

The perioperative use of tranexamic acid (TXA) has been extensively studied in various surgical contexts, including general surgery, to evaluate its efficacy in reducing blood loss, the need for transfusion, and major bleeding events, as well as its safety profile concerning thromboembolic events and mortality.

Key Findings on Perioperative Use of Tranexamic Acid:

1. Reduction in Blood Loss:

• TXA has been shown to significantly reduce intraoperative blood loss. In a systematic review and meta-analysis of 26 randomized clinical trials (RCTs) involving 6976 patients, TXA use was associated with a mean reduction of 35.85 mL in intraoperative blood loss compared to placebo.

2. Reduced Need for Transfusion:

• The use of TXA was linked to a 25% reduction in the risk of requiring blood transfusions during or after surgery (Risk Ratio [RR], 0.75). This suggests that TXA can effectively minimize the need for blood products in the perioperative setting.

3. Lower Risk of Major Bleeding Events:

• TXA use was associated with a 28% reduction in the risk of major bleeding events (RR, 0.72). This highlights its role in improving hemostasis during surgical procedures.

4. No Significant Increase in Thromboembolic Events:

• Concerns about TXA increasing the risk of venous thromboembolism (VTE) were not substantiated in the meta-analysis. The risk of VTE remained comparable between TXA and placebo groups (RR, 1.09).

5. No Increase in Mortality:

• TXA did not significantly affect mortality rates (RR, 1.08), indicating that its perioperative use is safe in terms of survival outcomes.

6. Impact on Length of Stay:

• While TXA was associated with a slight reduction in hospital length of stay, the difference was not statistically significant.

Considerations and Subgroup Analyses:

• Procedure-Specific Efficacy:

• The benefits of TXA were not consistent across all types of general surgical procedures. For example, in abdominal surgeries, the reductions in blood loss and transfusion requirements observed in the overall analysis were not significant.

• In hepatobiliary surgeries, TXA was particularly effective in reducing major bleeding events (RR, 0.59).

• Heterogeneity in Results:

• The systematic review noted some heterogeneity in outcomes, which may reflect differences in surgical procedures, patient populations, and TXA dosing regimens.

Safety Profile:

• TXA was not associated with increased risks of thromboembolic events, such as deep vein thrombosis (DVT) or pulmonary embolism (PE), which have historically been concerns with antifibrinolytic agents.
• No significant increase in mortality was observed, further supporting the safety of TXA use in perioperative settings.

Clinical Implications:

• Individualized Decision-Making:

• While TXA has demonstrated efficacy and safety in reducing perioperative bleeding, its use should be tailored to the specific surgical procedure and patient characteristics.

• Factors such as the type of surgery, baseline risk of bleeding, and patient comorbidities should guide the decision to use TXA.

• Potential for Broader Use:

• TXA may be a valuable tool in reducing the need for blood transfusions and improving surgical outcomes, particularly in procedures with a high risk of bleeding. However, its benefits may not be universal across all types of general surgery.

Conclusion:

The perioperative use of tranexamic acid is associated with significant reductions in blood loss, transfusion requirements, and major bleeding events, without an increased risk of thromboembolic complications or mortality. However, its benefits may vary depending on the type of surgery and patient population, necessitating a case-by-case approach to its use.